Gene therapy strategies for the treatment of chronic viral hepatitis

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2001-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14712598.1.4.629PMID 11727499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Envelope Protein-Mediated Down-Regulation of Hepatitis B Virus Receptor in Infected Hepatocytes

  2001cited by this paper
• Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

  2000cited by this paper
• Cytokine-mediated control of viral infections.

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• AAV vectors: is clinical success on the horizon?

  2000cited by this paper
• Development of biomaterials for gene therapy.

  2000cited by this paper
• Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium

  2000cited by this paper
• Current therapy for chronic hepatitis C.

  2000cited by this paper
• Synthetic DNA delivery systems

  2000cited by this paper
• Pretreatment with Protease Is a Useful Experimental Strategy for Enhancing Adenovirus-Mediated Cancer Gene Therapy

  2000cited by this paper
• DNA delivery systems based on complexes of DNA with synthetic polycations and their copolymers.

  2000cited by this paper
• Biodistribution, metabolism, and in vivo gene expression of low molecular weight glycopeptide polyethylene glycol peptide DNA co-condensates.

  2000cited by this paper
• Gene therapy: trials and tribulations

  2000cited by this paper
• Cationic Polymer Based Gene Delivery Systems

  2000cited by this paper
• Obstacles and advances in non-viral gene delivery.

  2000cited by this paper
• Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B

  2000cited by this paper
• Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

  2000cited by this paper
• Liver-Specific Alpha 2 Interferon Gene Expression Results in Protection from Induced Hepatitis

  2000cited by this paper
• Therapeutic efficacy of DNA encoding IFN-alpha1 against corneal HSV-1 infection.

  2000cited by this paper
• Impact of acute hepatitis B virus superinfection on chronic hepatitis c virus infection

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• Therapeutic efficacy of DNA encoding IFN-a1 against corneal HSV-1 infection

  2000cited by this paper
• Effects of Physicochemical Characteristics of Poly(2-(dimethylamino)ethyl methacrylate)-Based Polyplexes on Cellular Association and Internalization

  2000cited by this paper
• Adenovirus vectors for gene delivery.

  1999cited by this paper
• Sustained correction of bleeding disorder in hemophilia B mice by gene therapy.

  1999cited by this paper
• Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro.

  1999cited by this paper
• Synthetic Oligonucleotides: The Development of Antisense Therapeutics

  1999cited by this paper
• Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA

  1999cited by this paper
• Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon

  1999cited by this paper
• Adenovirus-mediated gene therapy of liver diseases.

  1999cited by this paper
• Ectopic expression of DNA encoding IFN-alpha 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis.

  1999cited by this paper
• Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector

  1999cited by this paper
• High-efficiency gene transfer into skeletal muscle mediated by electric pulses.

  1999cited by this paper
• Gene therapy of viral hepatitis and hepatocellular carcinoma

  1999cited by this paper
• A Pressure-Mediated Nonviral Method for Efficient Arterial Gene and Oligonucleotide Transfer

  1999cited by this paper
• Hepatitis B virus transgenic mouse model of chronic liver disease

  1999cited by this paper
• High Levels of Foreign Gene Expression in Hepatocytes after Tail Vein Injections of Naked Plasmid DNA

  1999cited by this paper
• Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection.

  1999cited by this paper
• Branched Cationic Peptides for Gene Delivery: Role of Type and Number of Cationic Residues in Formation and in Vitro Activity of DNA Polyplexes

  1999cited by this paper
• Simple Mixing of IFN with a Polysaccharide Having High Liver Affinity Enables IFN to Target to the Liver

  1999cited by this paper
• Application of membrane-active peptides for nonviral gene delivery.

  1999cited by this paper
• Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease

  1998cited by this paper
• Pre-treatment with elastase improves the efficiency of percutaneous adenovirus-mediated gene transfer to the arterial media

  1998cited by this paper
• Beta Cyclodextrins Enhance Adenoviral-Mediated Gene Delivery to the Intestine

  1998cited by this paper
• Synthetic peptide-based DNA complexes for nonviral gene delivery.

  1998cited by this paper
• The efficient expression of intravascularly delivered DNA in rat muscle

  1998cited by this paper
• Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen‐negative patients

  1998cited by this paper
• Interpolyelectrolyte and block ionomer complexes for gene delivery: physico-chemical aspects.

  1998cited by this paper
• Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia

  1998cited by this paper
• Antiviral activities of individual murine IFN-alpha subtypes in vivo: intramuscular injection of IFN expression constructs reduces cytomegalovirus replication.

  1998cited by this paper
• Gene transfer into muscle by electroporation in vivo.

  1998cited by this paper
• Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery.

  1998cited by this paper
• The treatment of chronic viral hepatitis.

  1997cited by this paper
• Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C.

  1997cited by this paper
• Factor IX inhibitors and anaphylaxis in hemophilia B.

  1997cited by this paper
• Dioleoylmelittin as a novel serum-insensitive reagent for efficient transfection of mammalian cells.

  1997cited by this paper
• Posttranscriptional regulation of hepatitis B virus replication by the precore protein

  1997cited by this paper
• Gene therapy for chronic viral hepatitis: Ribozymes, antisense oligonucleotides, and dominant negative mutants

  1997cited by this paper
• The Influence of Sodium Glycocholate and Other Additives on the in vivo Transfection of Plasmid DNA in the Lungs

  1996cited by this paper
• Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein

  1996cited by this paper
• Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers.

  1996cited by this paper
• Hepatitis B virus X protein partially substitutes for E1A transcriptional function during adenovirus infection.

  1996cited by this paper
• Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication

  1996influential reference
• The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice

  1996cited by this paper
• Hepatitis B virus transgenic mice: Insights into the virus and the disease

  1995cited by this paper
• Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents

  1995cited by this paper
• The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants.

  1995cited by this paper
• Surfactant Protein A–Polylysine Conjugates for Delivery of DNA to Airway Cells in Culture

  1995cited by this paper
• Role of hepatitis C virus in dual and triple hepatitis virus infection

  1995cited by this paper
• Factor VIII inhibitors

  1995cited by this paper
• A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.

  1995cited by this paper
• Treatment of chronic viral hepatitis.

  1994cited by this paper
• Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy.

  1994cited by this paper
• Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice.

  1994cited by this paper
• Characterization of hepatitis B virus core mutants that inhibit viral replication.

  1994cited by this paper
• Pharmacological enhancement of in vivo foreign gene expression in muscle.

  1994cited by this paper
• Factor VIII inhibitors

  1993cited by this paper
• Repression of liver-specific hepatitis B virus enhancer 2 activity by adenovirus E1A proteins

  1992cited by this paper
• Adenovirus infection induces amplification of persistent viral DNA sequences (simian virus 40, hepatitis B virus, bovine papillomavirus) in human and rodent cells.

  1990cited by this paper
• Effects of HIV superinfection on HBV replication in a chronic HBsAg carrier with liver disease.

  1988cited by this paper
• Medical Physiology

  1957cited by this paper
• On Diseases of the Liver

  1903cited by this paper

• Inhibition effect produced by dominant negative mutant fusion protein PreS2‐TLM‐ScFv‐HBcDN on HBV replication in vitro

  2012cites this paper
• Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon

  2009cites this paper
• Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings.

  2008cites this paper
• NON-VIRAL GENE DELIVERY WITH pH-SENSITIVE GEMINI NANOPARTICLES: SYNTHESIS OF GEMINI SURFACTANT BUILDING BLOCKS, CHARACTERIZATION AND IN VITRO SCREENING OF TRANSFECTION EFFICIENCY AND TOXICITY

  2008cites this paper
• Tratamiento de la enfermedad hepática crónica inducida por el virus de la hepatitis C: bases moleculares y celulares.

  2006cites this paper
• Anti-HBV activity of TRL mediated by recombinant adenovirus.

  2005cites this paper
• VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication.

  2005cites this paper
• Biotechnology-Derived Pharmaceuticals

  2005cites this paper
• COLABORACIÓN ESPECIAL Terapia génica: ¿Qué es y para qué sirve? Gene therapy: what is it and what is its use?

  2005cites this paper
• Preclinical safety testing of biotechnology-derived pharmaceuticals

  2004cites this paper
• Polyamines and novel polyamine conjugates interact with DNA in ways that can be exploited in non-viral gene therapy.

  2003cites this paper
• Inhibition of HBV targeted ribonuclease enhanced by introduction of linker.

  2003cites this paper
• Pretreatment with Protease Is a Useful Experimental Strategy for Enhancing Adenovirus-Mediated Cancer Gene Therapy

  2000cites this paper